Pharmaceutical

Boehringer seeks approval of lung disease drug after second Phase III success

Nerandomilast is posed to be Boehringer Ingelheim’s successor to its blockbuster Ofev (nintedanib)in IPF and PPF.

Feb 11, 2025 - 06:00
Boehringer seeks approval of lung disease drug after second Phase III success
Nerandomilast is posed to be Boehringer Ingelheim’s successor to its blockbuster Ofev (nintedanib)in IPF and PPF.
Read the original article

Tags:

Previous Article

Bio-Thera signs US deal with Intas for golimumab biosimilar

Next Article

Public health strategies skip patients with rare diseases, says UK study

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: U.S. Supreme Court declines bid by Teva to hear ‘skinny labeling’ case with implications for generic drug access

STAT+: U.S. Supreme Court declines bid by Teva to hear ...

May 15, 2023

Bristol Myers Squibb acquires Karuna Therapeutics for $14bn

Bristol Myers Squibb acquires Karuna Therapeutics for $...

Mar 20, 2024

STAT+: FDA inspection underscores problem at major U.S. compounder behind hospital drug recalls

STAT+: FDA inspection underscores problem at major U.S....

Jul 26, 2023